This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HBV infections often result in chronic infections that progress to cirrhosis and liver cancer. HBV infections are the fourth leading cause of death due to infectious disease world wide and 350 million people are chronic carriers. Current antivirals are not satisfactory and do not lead to viral clearance. They must be taken for life and eventually resistance makes them useless. It is essential that improved antivirals be developed for this disease. The sponsor of this study has developed a very potent and specific antiviral for hepatitis B virus. Prior to entering into human clinical trials, it is necessary to ensure that the compound inhibits viral replication in an animal model. Chimpanzees are the only animal other than man that can be infected by HBV. This study will be conducted in two phases, PK and efficacy.
Showing the most recent 10 out of 444 publications